[{"company":"Clover Biopharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover and GSK Announce Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Beijing Advaccine Biotechnology","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Beijing Advaccine Biotechnology"},{"company":"Stemirna Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pilot testing of potential COVID-19 vaccine progresses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Stemirna Therapeutics"},{"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Announces COVID-19 Vaccine Development Partnership With Clover Biopharmaceuticals\u2019 Australian Subsidiary","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Clover Biopharmaceuticals"},{"company":"Sinovac Biotech","sponsor":"Institut of Butantan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sinovac Biotech"},{"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Henlius Biotech, Inc. (2696 HK) \u2013 Expecting five NDA Approvals Within Two Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Henlius Biotech"},{"company":"STA Pharmaceutical","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"STA Pharmaceutical"},{"company":"WuXi Biologics","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biovaxys Inks Agreement With WuXi Biologics to Synthesize Proteins for Its Sars-CoV-2 Vaccine and Covid-T\u2122 Immunodiagnostic Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"WuXi Biologics"},{"company":"Hainan Poly Pharm Co. Ltd","sponsor":"Celsion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion\u2019s DNA-based Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Hainan Poly Pharm Co. Ltd"},{"company":"Shanghai Zhijiang Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bispecific Antibody Drug Against Covid-19 Jointly Developed By Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals Appearing at China International Import Expo (CIIE)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Zhijiang Biotechnology"},{"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Institute of Materia Medica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Simcere Pharmaceutical"},{"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Business Update on ASC10, an Oral Double Prodrug Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascentage Pharma"}]
Details:
HQP1351 (olverembatinib) inhibited a panel of the Omicron-NTD-mediated cytokines tested, with a EC50 between 7.7 and 56 nM, demonstrating a wider range of concentrations than that of baricitinib.
Lead Product(s):
Olverembatinib
Therapeutic Area: Infections and Infectious Diseases
Product Name: HQP1351
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 19, 2022
Details:
New experimental data indicated that ASC10-A, an oral double prodrug of the antiviral nucleoside analog A showed potent cellular antiviral activity against Omicron variant (EC50 = 0.3µM), Delta variant (EC50 = 0.5µM) and wildtype virus (EC50 = 0.7µM).
Lead Product(s):
ASC10-A
Therapeutic Area: Infections and Infectious Diseases
Product Name: ASC10-A
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 15, 2022
Details:
SYZJ001 is screened from the "Ten-Trillion Innovative Antibody Discovery Platform", a platform over which Sanyou Biopharmaceuticals has independent intellectual property rights.
Lead Product(s):
SYZJ001
Therapeutic Area: Infections and Infectious Diseases
Product Name: SYZJ001
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 22, 2021
Details:
Under the arrangement, Simcere will obtain the exclusive right to develop, manufacture and commercialize the novel antiviral drug SIM0417 globally. Mutually striving to further contribute to the fight against the COVID-19 pandemic, both parties committed to working together.
Lead Product(s):
SIM0417
Therapeutic Area: Infections and Infectious Diseases
Product Name: SIM0417
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Shanghai Institute of Materia Medica
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
November 17, 2021
Details:
Under the terms of agreement, Poly Pharm will manufacture clinical batches and, if approved, will also manufacture commercial batches for Celsion’s vaccine based on TheraPlas technology. TheraPlas underlies Celsion’s GEN-1 product and its PLACCINE vaccine technology platform.
Lead Product(s):
DNA-based COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Placcine Covid 19 Vaccine
Highest Development Status: Preclinical
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Celsion Corporation
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
September 17, 2021
Details:
Under the terms of the agreement, WuXi Bio will synthesize high yields of fully characterized, Good Laboratory Practice (GLP) grade SARS-CoV-2 s-protein required by BioVaxys for BVX-0320, its COVID-19 vaccine candidate, and for its Covid-T™ immunodiagnostic program.
Lead Product(s):
SARS-CoV-2 s-protein based vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: BVX-0320
Highest Development Status: Preclinical
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Biovaxys
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
March 15, 2021
Details:
Qualigen Therapeutics has signed a contract with STA Pharmaceutical, a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials.
Lead Product(s):
AS1411
Therapeutic Area: Infections and Infectious Diseases
Product Name: AS1411
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Qualigen Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
November 05, 2020
Details:
The Company actively involves in development of anti-COVID-19 drugs with two candidates in pre-clinical phase, including HLX71 (S1 protein), and HLX70 (S1 protein).
Lead Product(s):
HLX71
Therapeutic Area: Infections and Infectious Diseases
Product Name: HLX71
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 13, 2020
Details:
This collaboration focuses on the clinical development to advance the clinical trials of CoronaVac, Sinovac’s inactivated vaccine candidate against COVID-19 to Phase III.
Lead Product(s):
Inactivated vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Institut of Butantan
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
June 11, 2020
Details:
CEPI to provide funds to Clover Biopharmaceuticals Australia to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in Australia.
Lead Product(s):
COVID-19 S-Trimer
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Vaccine
Partner/Sponsor/Collaborator:
CEPI
Deal Size: $3.5 million
Upfront Cash: Undisclosed
Deal Type: Funding
April 27, 2020
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
